Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Warfarin-5-FU interaction--a consecutive case series.

J M Kolesar1, C L Johnson, B L Freeberg

  • 1School of Pharmacy, University of Wisconsin-Madison, 53706-1515, USA.

Pharmacotherapy
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.

ESMO open·2024
Same author

Infertility prevalence and the methods of estimation from 1990 to 2021: a systematic review and meta-analysis.

Human reproduction open·2022
Same author

Proton deflectometry with in situ x-ray reference for absolute measurement of electromagnetic fields in high-energy-density plasmas.

The Review of scientific instruments·2022
Same author

Brain-mimicking phantom for biomechanical validation of motion sensitive MR imaging techniques.

Journal of the mechanical behavior of biomedical materials·2021
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Lessons learnt from the field: a qualitative evaluation of adolescent experiences of a universal mental health education program.

Health education research·2020
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Warfarin dosage must be reduced when co-administered with 5-fluorouracil (5-FU) chemotherapy. This interaction can lead to dangerous bleeding events, necessitating close monitoring of warfarin therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Internal Medicine

Background:

  • Warfarin is a common anticoagulant.
  • 5-fluorouracil (5-FU) is a widely used chemotherapy agent.
  • Drug interactions between anticoagulants and chemotherapy can significantly impact patient safety.

Purpose of the Study:

  • To investigate the clinical significance of the interaction between warfarin and 5-FU.
  • To assess the impact of 5-FU chemotherapy on warfarin dosage requirements.
  • To evaluate the safety and efficacy of concomitant warfarin and 5-FU administration.

Main Methods:

  • Retrospective case series of five patients receiving concurrent warfarin and 5-FU.
  • Analysis of warfarin dosage adjustments before and during 5-FU chemotherapy.

Related Experiment Videos

  • Monitoring of international normalized ratios (INRs) and adverse events, including bleeding.

    • Main Results:

    • A significant reduction in mean weekly warfarin dose was observed during 5-FU chemotherapy (40.66 mg to 24 mg, p=0.0026).
    • All patients required warfarin dosage reduction, averaging 44% (range 18-74%).
    • Two patients experienced significant bleeding events requiring hospitalization, with maximum INRs reaching 23.7.

    Conclusions:

    • A clinically significant interaction exists between warfarin and 5-FU, necessitating warfarin dose reduction.
    • The interaction extends to capecitabine, an oral prodrug of 5-FU.
    • Weekly monitoring of prothrombin time and INR is recommended for patients on concurrent warfarin and 5-FU or capecitabine.